Arbutus Biopharma Corporation (NASDAQ:ABUS)‘s stock had its “buy” rating reissued by Chardan Capital in a research report issued on Monday.
Several other brokerages also recently issued reports on ABUS. Zacks Investment Research downgraded shares of Arbutus Biopharma Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Ladenburg Thalmann Financial Services assumed coverage on shares of Arbutus Biopharma Corporation in a report on Friday, June 2nd. They set a “buy” rating and a $32.00 price target for the company. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $11.65.
Shares of Arbutus Biopharma Corporation (NASDAQ ABUS) opened at 3.65 on Monday. The stock’s market cap is $200.84 million. The company has a 50-day moving average of $3.67 and a 200 day moving average of $3.23. Arbutus Biopharma Corporation has a 52-week low of $2.35 and a 52-week high of $4.10.
COPYRIGHT VIOLATION NOTICE: “Arbutus Biopharma Corporation (ABUS) Rating Reiterated by Chardan Capital” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/08/09/arbutus-biopharma-corporation-abus-rating-reiterated-by-chardan-capital.html.
Several large investors have recently modified their holdings of the stock. Bank of Montreal Can boosted its stake in shares of Arbutus Biopharma Corporation by 1.9% in the second quarter. Bank of Montreal Can now owns 874,254 shares of the biopharmaceutical company’s stock worth $3,147,000 after buying an additional 16,535 shares in the last quarter. Victory Capital Management Inc. bought a new stake in shares of Arbutus Biopharma Corporation during the second quarter worth $478,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Arbutus Biopharma Corporation by 785.1% in the first quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 110,499 shares in the last quarter. Institutional investors and hedge funds own 66.53% of the company’s stock.
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
